Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids

Efficacy of Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids Following Bariatric and Minimally Invasive Foregut Surgery

Status

Withdrawn

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04655339

Enrollment

Registered

2020-12-07

Start date

2020-01-24

Completion date

2021-09-03

Last updated

2026-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use

Brief summary

This study evaluates laparoscopic-guided TAP block for reducing opioid use after minimally invasive foregut and bariatric surgeries, comparing Bupivacaine HCL with Exparel®. Secondary outcomes include pain scores, length of stay, and PONV medication use.

Detailed description

In this study the investigators aim to investigate the efficacy of laparoscopic-guided TAP block in reducing post-operative opioid use following minimally invasive foregut and bariatric surgeries. The investigators will also compare and report the analgesia produced by Bupivacaine HCL vs Exparel ®, a prolonged slow release Liposomal Bupivacaine formulation. Secondary outcomes assessed will be VAS pain scores, length of stay, and PONV dosage administered.

Interventions

DRUGBilateral abdominal Lap-TAP

Subjects will have Liposomal Bupivacaine (Exparel®) or the control injected into the transversus abdominis plane bilaterally.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* gastric bypass \& sleeve gastrectomy, duodenal switch and minimally invasive elective anti-reflux foregut surgeries such as - hiatal hernia repair, fundoplication and Heller myotomy.

Exclusion criteria

* Subjects who are known to be * Allergic to Bupivacaine * Chronic opioid users Page 4 * Had/have neurological conditions * Have a diagnosis of chronic pain syndrome which requires them to consume regular analgesics \> 3-months * American Society of Anesthesiologists (ASA) Class IV \& V patients with severe systemic disease that is a constant threat to life. * Patients with abdominal drain use * Patients with significant cardiovascular, liver or renal disease * Presence of contraindications for bariatric or foregut surgery. * Patients presenting postoperative complications will be excluded from final analysis \& final data set * History of bariatric or foregut surgery * Patients who are pregnant * Patients who are under the age of 18

Design outcomes

Primary

Measure	Time frame	Description
opioid dosage requested	30days	opioid dosage requested post-TAP block

Secondary

Measure	Time frame
visual analog scores (VAS)	30days
length of stay	30days
anti-emetic dosage	30days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026